VBI Vaccines Inc/BC: M&A transaction — VBI Vaccines completes sale to K2 HealthVentures affiliate; common shares cancelled for no value, company to deregister

VBI Vaccines Inc/BC

All outstanding common shares redeemed and cancelled without consideration; existing shareholders receive zero.
Company and subsidiaries become wholly owned by K2 VBI Equity Trust (K2 HealthVentures affiliate) and exit CCAA protection.
All directors and executive officers resigned; replaced by nominees of K2.
Company plans to cease reporting issuer status in Canada and deregister shares under SEC.
Transaction closed January 3, 2025, per court-approved acquisition agreement dated Oct 24, 2024.

item 2.01 item 3.03 item 5.01 item 5.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.95

VBI Vaccines Inc/BC underwent a change of control involving K2 VBI Equity Trust, LLC for all previously issued and outstanding common shares of the Company have been redeemed and cancelled without consideration; new shares issued to Purchaser in con (closed 2025-01-03).

Action: change of control
Counterparty: K2 VBI Equity Trust, LLC
Consideration: all previously issued and outstanding common shares of the Company have been redeemed and cancelled without consideration; new shares issued to Purchaser in con
Closing: 2025-01-03

Exact text from the filing

On January 3, 2025, the Company completed the transactions (collectively, the

View on SEC.gov

Browse all m&a transactions →

Source: SEC EDGAR

accession 0001493152-25-000271

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.